Multiple layer filamentary devices for treatment of vascular defects

Abstract
Braid-balls suitable for aneurysm occlusion and/or parent vessel occlusion/sacrifice (e.g., in treating neurovascular defects) are disclosed. Especially for aneurysm treatment, but also for either one of the aforementioned treatments, the form of the ball is very important. In particular, the density of the device is paramount in applications where braid itself is intended to moderate or stop blood flow—allowing thrombosis within a volume formed by the ball.
Description
TECHNICAL FIELD

The present invention is directed to braid-balls suitable for aneurysm occlusion and/or parent vessel occlusion/sacrifice (e.g., in treating neurovascular defects).


BACKGROUND

Mainstream clinical practice in endovascular treatment of intracranial aneurysms has changed little since the 1990's when vasoocclusive coil use became widespread. Certainly, improved catheters and other auxiliary devices (e.g., stents) have helped make coiling procedures safer and/or more effective. However, the art in achieving adequate and appropriate aneurysm coil packing is best accomplished by the most highly skilled physicians.


Where practicable, aneurysm exclusion by cover-type devices (e.g., as described in U.S. patent application Ser. No. 12/397,123 to the assignee hereof) may be preferred. Certain other groups are attempting to shift the paradigm away from intra-aneurysm coil packing to achieve embolization via deployment of an extra-aneurysm flow disruptor/diverter stent in the parent vessel. These densely braided devices and/or multiple braid devices layered upon one another are placed in the parent vessel across the neck of an aneurysm with the intent to alter hemodynamics so as to effect embolization.


These WALLSTENT-like devices are best suited for placement across sidewall aneurysms. Yet, terminal aneurysms (e.g., bifurcation aneurysms) are estimated by some to make-up between about 60 and 80% of all aneurysm occurrences. By most optimistic count, only about 40% of intracranial aneurysms can be treated using the referenced stent-like devices.


Numerous other devices have been conceived in effort to address terminal aneurysms. Complicated and/or impracticable deployment is common to many. Others simply serve as adjunctive to coils or liquid embolic agents. In these latter examples, procedures may become even more complicated and require even greater physician skill than a standard coiling procedure.


A simpler, yet promising solution is proposed in PCT/US 2007/0076232 to Dieck, et al. A braided/mesh conical member is described for diverting blood flow from the aneurysm neck. A base of the device is set inside the aneurysm while a flow diverter portion extends into the parent vessel to direct blood flow toward adjacent side branches and away from the aneurysm. The implant may be positioned within the aneurysm as a stand-alone device or be supported by a connected stent-like body.


U.S. Pat. Nos. 6,168,622 and 6,506,204 to Mazzochi, et al. disclose another type of braided flow disruptor set at least partly within an aneurysm. A bulbous portion is adapted to fit within the aneurysm dome and is anchored on the outside by a neck-covering flap. Given the manner in which bifurcation aneurysms often incorporate branch vessel anatomy, such a patch would often interfere with and/or “flap” free raising significant issues of potentially pathological thrombus formation within the parent vessel.


SUMMARY OF THE INVENTION

Implants of the present invention address shortcomings of each of the above-referenced devices. As such, the subject implants (as well as their associated delivery systems) offer potential to advance the state of the art in endovascular treatment of vascular malformations, including aneurysms.


The present invention is directed to wire braid ball implants for occluding blood flow at endovascular sites. Delivery systems and methods of making the balls are also described. The balls are useful for treating neurovascular defects. One use is in intracranial aneurysm embolization/occlusion and another in parent vessel occlusion (PVO) or sacrifice.


Generally speaking, the subject vascular implants are braided devices using a combination of bio-stable materials selected from Stainless Steel, Cobalt Chromium, Nitinol, Titanium, Titanium-alloys, Zirconium and Zirconium alloys, PET (or another suture material) and medical-grade adhesive. The density of the device is paramount in applications where the braid itself is intended to affect blood flow, allowing thrombosis within a volume formed by the ball to occlude a site. As such, high density braid/mesh is typically required. Namely, braid having at least about 48 ends, typically set at about 90 degrees or greater, in diameters from about 4 to about 8 mm may be employed. At larger diameters (e.g., about 6 mm to 12 mm or more), more wire ends (e.g., common multiples of 64, 72, 96, 128, 144) may be employed in forming the balls. Still higher typical wire counts may be employed. Either one of commercially available 192 and 288 carrier standard braiders may be employed. Moreover, 3-D braiding technology (such services are provided by 3Tex, Inc.) may be employed in forming the braid matrix from which the balls are formed. In addition, any combination of wire diameter, wire count, braid angle, and per-inch crossings can be used to make braid in order to configure an embolic and blood flow occlusive device deemed appropriate for a particular vascular site.


A range of wire sizes or combination of wire sizes may be employed, typically ranging from about 0.0008 to about 0.0015 inch, and up to about 0.003 inches depending on desired delivery profile (which is typically desired to be less than about 0.050 inches—at least for neurovascular indications—and more generally up to about 0.070 for peripheral PVO indications). A single braid tube may have all wires the same diameter, or may have some wires of a slightly thicker diameter to impart additional strength to the braid layer. For example, half the wires of a 96 wire tube (i.e., 48 ends) can be e.g. 0.001″ diameter and the other half of the wires can be e.g. 0.0015″ diameter. In which case, the two wire sizes would typically be interlaced uniformly in making the braid. The thicker wires impart greater strength to the braid without significantly increasing the device delivery profile, with the thinner wires offering some strength while filling out the braid matrix density.


The wire is preferably NiTi alloy that is superelastic at body temperature. The metal may be a binary alloy or a ternary alloy to provide additional radiopacity. Alternatively, radiopaque platinum fibers may be included in the braid, or the wire may comprise platinum or gold core Nitinol DFT. Otherwise, hubs, bands or wraps (preferably Pt) used to secure the braid wire (at either or both distal and proximal ends, and also in between caps where appropriate) may serve as the sole radiopaque feature(s).


To improve implant wire corrosion resistance and/or biocompatibility after heat setting shape, the implants may be etched in “AYA” Sulfamic Acid solution, then passivated in Nitric acid solution. Alternatively or additionally, pre-etched and/or polished wire may be employed in braiding the implant matrix. Shape setting the braid in the implant shape may be performed in an oven/furnace, a fluidized bath or salt pot. All such processing is within ken of those with ordinary skill in the art.


Especially after heatsetting the shape, the wire may be coated with an agent for promoting a desired biological effect. For example, wire can be coated with a thrombogenic or an endothelization agent, or other agent capable of promoting a desired biological process at the target site. The braid balls may also be partially or fully coated on the exterior (e.g., with coating such as urethane) to increase the occlusive effect of the ball, provided the coating does not cause the delivery profile of the final device to exceed allowed limits. Hydrogel coating also offers an appealing option, such as a hydrogel-based polymer network capable of entrapping therapeutic agents as described in U.S. Pat. No. 6,905,700 to Won et al.


Likewise, while the balls advantageously comprise Nitinol braid, the braid may instead comprise polymer—especially high strength biodegradable polymer such as MX-2 (MAX-Prene), synthetic absorbable monofilament (90/10 Glycolide/L-Lactide) and/or G-2 (Glycoprene), synthetic absorbable monofilament (Glycolide (PGA), ε-Caprolactone (PCL), Trimethylene Carbonate (TMC) Copolymer) that is heat set into shape (e.g., at 110 degrees centigrade for an hour).


Deliverability of the subject implants to certain neurovascular sites (e.g., distal intercranial aneurysms) often requires that they be compressible to pass through a catheter sized for navigating the narrow and tortuous vessels of the brain. Standard neurovascular catheters suitable for such use have 0.021″ and 0.027″ lumen diameters. Especially for higher wire count balls 0.027″ ID (e.g., Cordis Mass Transit Boston Scientific Renegade HI-FLO) or larger (e.g., 0.044″ ID Concentric Merci Distal Access Catheter) commercially available micro catheters may be preferred. For devices adapted to address PVO indications in which higher wire counts and/or larger wire diameters are used to ensure anchoring, the implants may require 5 and/or 6 Fr guide catheters for delivery.


In any of the configurations described, the devices may comprise high-density Nitinol braid that is folded/doubled-back upon itself and heatset to provide an open body having two adjacent layers forming an even denser matrix to occlude blood flow. The folded-back (inverted or everted) section may be closed to define a distal end of the device where a radiopaque feature may be located. At the opposite side of the implant, braid filaments are held in a hub including at least an outer band.


A port within the hub can receive component(s) of an optional detachable pusher. Alternatively, the implant can be deployed through a catheter using a simple pusher. Braid filaments within the hub(s) may be welded to each other and/or the band. Alternatively, the braid and hub(s) may be secured using biocompatible adhesive.


In a relaxed state, the implants define an open, preferably rounded, volume. In a delivery catheter, they compress into a substantially cylindrical body. When deployed at a treatment site, they expand to abut surrounding tissue and occlude flow in a clinically relevant timeframe.


Use of a detachable pusher allows for deploying a device (e.g., in an aneurysm) and checking fit. Deployed in an aneurysm to occlude the aneurysm at its neck, the implant device largely assumes the shape of the aneurysm, with the proximal hub and closely adjacent braid material outside the neck. To achieve such fit, the implants are provided in a range of sizes. These may progress in 0.5 mm to 1 mm diameter increments. For aneurysm treatment at bifurcations, it may also be desirable if the ball (at least in its delivered configuration) assumes a tear-drop shape to assist in a flow-divider/diverter type function as described in Dieck, et al., referenced above.


Should the selected implant not fit as desired, however, it can simply be withdrawn back into the delivery catheter. If desired fit is achieved (with the first implant or a replacement) as confirmed by medical imaging, the implant is released.


An electrolytically-releasable GDC-type joint can be used hold the implant secure to the pusher until release. Details regarding suitable electrolytic detachment systems can be appreciated and applied to the current system as taught in U.S. Pat. No. 5,122,136 to Guglielmi and continuing applications thereof—all of which are herein incorporated by reference. Another electrically-powered detachment approach employs a meltable fiber or suture junction connecting the implant to the delivery pusher/guide. In such a system, a polymeric core may be configured with helically wound conducting ribbons held to the core. Upon application of voltage, sufficient current is conveyed through the ribbons to a wire bridge connecting them. Heat generated along the bridge, optionally NiChrome wire, severs the suture that is tied onto or running adjacent to the bridge in order to release the implant. Further details of a suitable suture-melt detachment systems are described in the incorporated provisional applications.


Yet, mechanical detachment systems may be more preferred. An aspect of the present invention involves pushers in which at least one member provides mechanical interference at/with the implant hub port to releasably lock the implant onto the pusher. In one approach, a wire or ribbon exiting an extension of the pusher threaded through the port produces such interference until it is withdrawn. In another example, a plurality of wires/ribbons are received through the port. One or more (typically two or three) of these wires extend through a pusher catheter body to a proximal handle interface. A final “anchor” wire received through the port may also extend to the handle. The anchor wire includes a head sized to exit the hub port only after the other “control” wires are cleared therefrom. The head is preferably formed by laser or plasma heating/melting. The handle provides a user interface to first remove the control wires, and then (optionally) also pull the final anchor wire.


To assist in implant recapture should it not be released, a smooth lead-in/trumpet shaped recapture profile may be provided between the hub and main body of the implant. In another approach relevant in a two-layer implant, no such profile is provided. Rather only the outer of braid layer is secured within the hub, and the inner layer “floats”. In this way, only the outer layer must be straightened relative to the hub to retrieve the ball within the catheter/sheath, with the inner layer riding along.


In order to permit such action, the braid matrix must remain stable and interlocked. Accordingly, when feasible, a one-over-one braid pattern will be preferred. In addition, the braid should be trimmed adjacent the hub where the hub-secured braid is most dense. So configured, the outer braid both serves as a guide and is of such density to prevent loose ends of the inner layer from poking through. Whereas a floating-layer type ball implant would typically only be used for an aneurysm indication due to reduced radial strength, the recapture profile may be used on either an implant intended for aneurysm or PVO use.


Recapture features aside, when deployed in a vessel for use in parent vessel occlusion, the subject implant is “sausage” shaped. For such purposes, it may be desirable that the compressed length of the ball is minimized relative to its diameter. Proximal and/or distal ends of the ball may be flattened or flatter (such that the ball is more “donut” shaped) for this purpose.


Oversizing the device relative to the vessel provides adequate radial force to anchor its position against blood flow/pressure. To generate more anchoring force within a vessel for a PVO-dedicated implant (i.e., of a given deployed length), the ball may be formed in a shape having an elliptical cross-section. To offer further improved vessel anchoring, a cylindrical waist may be incorporated in the shape. Edges formed will concentrate stresses on the vessel wall in some cases to improve anchoring. Yet, the bulk shape allows the implant to work within a wide range of vessel sizes. Indeed, one size may fit a wide range of vessel diameters (e.g., a 10 mm ball suitable for 3-5 mm vessels, etc.).


In either type of implant (i.e., aneurysm or PVO), an advantageous construction involves folding or doubling-back the braid during manufacture to produce a two-layer matrix. A medial crease or fold in the braid is formed that is used in defining one end of the implant.


The fold may be pre-set in the braid or formed when fixturing the braid for shape setting. In the former case, the bend is pre-set by heatsetting the braid when confined in a tight tubular shape (e.g., by a crimper or at least partially within a hypotube). In the latter case, the braid is tied with suture at a point, a form is inserted in the open end of the braid tube and the braid is stretched, or positioned, over the form with the folded section under compression. When heated to set the shape, the suture burns away as the compression force sets the fold at a minimal radius.


The fold itself proves useful in a number of ways. In one variation of the invention, the folded section provides an atraumatic end to the implant. The folded section can be left open, or tied closed by a suture, wire (or other material) loop. If not radiopaque itself, the tie may also hold a marker band (knotted, glued or crimped on). If such a marker is provided, it may advantageously be suspended adjacent the top/distal end of the ball within the interior volume.


Either way, upon compression to a delivery profile, the implant body basically pivots (rather than bends) at the fold, thus minimizing in-catheter/sheath forces. This improves device trackability as well as delivery and the ability to recapture if treatment with another size device is desirable.


In a PVO-specific implant, a marker band can be held between braid layers adjacent the medial fold. The band is securely captured and “hidden” without presenting edges or other features. As such, the distal end of the device offers a smooth delivery/tracking profile without need to otherwise secure the band.


Utilized in any such fashion (i.e., open, tied or banded), joints and other delivery profile-increasing features are avoided at one end of the ball. As such, the fold offers constructional advantages (including improved manufacturability)—as well as reducing areas for failure where ends of the braid would otherwise need to be secured. Moreover, the doubled-over tubular stock achieves excellent density while ensuring consistent compression and shape-recovery performance since the layers are well matched. So-matched, they extend/foreshorten to substantially an equal degree when exiting and (re)entering the catheter.


One variation of the invention takes advantage of the matched braid layers, and simply eliminates the fold by grinding or otherwise cutting it away after heatsetting (and, optimally, braid hub securement). So-prepared, the implant becomes more radially compliant as may be desirable for aneurysm treatment. And without any additional space taken-up by the bend in the filaments, the ball can be further compressed for delivery through the smallest microcatheters (for a given braid density) to achieve access to more distal treatment sites.


Another variation of the invention may or may not be constructed using a folded-over approach. To achieve higher braid densities without stacking up additional layers having to fit within the microcatheter lumen, additional “cap” structures can be instead incorporated in the implant. For delivery, these features neck-down or compress in series. Yet, upon exit from the microcatheter, they recover to a position adjacent the main body of the implant.


The ball body and cap portions of the implant are typically constructed from a continuous section of braid. Intermediate marker sections may be provided between the elements. A hub including a delivery system port is provided at the proximal end of the device.


The proximal caps of braid provide additional braid layers to the device at an end where occlusion of blood flow is critical. The proximal end of a ball placed in an aneurysm contacts the opening and neck of the aneurysm. To achieve greater flow occlusion, the braid caps can be single or double layer braid. One or more braid caps can be placed at the proximal end of the ball (i.e., a braid ball can have up to three braid caps, and more if feasible).


The braid caps do not function, and are not adapted to function, as anchors for the device. An anchor holds fast or checks motion of an object attached to it. To anchor something is to fix or fasten, or affix firmly an object. The balls implants are not anchored in the aneurysm or parent vessel using the braid caps. Rather, the braid caps are designed to either be adjacent the ball within an aneurysm or to fill only the neck region. In either case, the caps do not substantially engage vascular tissue adjacent the ball. They serve as occlusive elements that enhance the ball's embolic potential.


As alluded to, two types of capped braid ball implants are provided. Caps adapted to fit only in the aneurysm neck are typically round (though they may be oval) and may be offered in a variety of sizes to fit different neck sizes just as the ball portion of the implant is offered in different sizes. In other words, across a whole line of implants, each of the cap size and ball size parameters may be varied.


The caps adapted to fit in an aneurysm adjacent the ball portion of the implant are larger and shaped to conform to the ball-shaped body. Their delivery requires either compressing the ball portion of the implant within the aneurysm and deploying the cap therein, or deploying the cap outside the aneurysm and pushing it into the aneurysm in a deployed state.


Delivery of the devices with the neck-filling cap(s) or disk(s) is performed substantially the same as braid balls without such feature(s) with the exception that the delivery catheter is withdrawn further to expose the cap(s) or the catheter is stationed outside the aneurysm neck (vs. at the neck) and the implant extruded therefrom. Of course, some combination of such activity may alternatively be employed.


In any case, if the desired fit is achieved, the implant is released. Otherwise, the implant is pulled into the delivery catheter from the proximal hub. The one or more caps compress to the linear profile of the delivery/retrieval sheath, followed by the ball portion.


In yet another variation of the invention, a braid-ball is used in conjunction with a stent. The ball may be attached to a stent, with them delivered together. Alternatively, a frame or cage may be provided at the end of a stent into which the braid-ball is delivered after the stent is in place. In either case, the ball and/or frame may be sized to fill substantially all of an aneurysm or only fill the neck. Either way, the stent will serve as an anchor to prevent the ball from migrating. The frame-plus-ball solution offers certain advantages in terms of staged deliverability, whereas the ball-topped stent offers a one-shot solution achievable in a single delivery. In each example, the stent may be either self-expanding (e.g., comprising superelastic Nitinol) or balloon-expandable (e.g., comprising stainless steel and mounted on a PTCA-type balloon). Regardless, the braid-ball implant employed may be any one of those described in the present filing or those cross-referenced above.


The present invention includes the subject devices, kits in which they are included, methods of use and manufacture. A number of aspects of such manufacture are discussed above. More detailed discussion is presented in connection with the figures below.





BRIEF DESCRIPTION OF THE FIGURES

The figures provided herein are not necessarily drawn to scale, with some components and features are exaggerated for clarity. Of these:



FIGS. 1A and 1B are side-sectional views illustrating braid ball implant variations in bifurcation and side-wall aneurysm locations, respectively, in which a folded section in each implant provides an atraumatic tissue interface;



FIG. 2 is a blow-up view of the implant pictured in FIG. 1B;



FIGS. 3A-3C are perspective side views of a folded-section braid ball in progressively larger sizes;



FIGS. 4A and 4B are side-sectional views illustrating proximal-flap braid ball implant variations deployed within bifurcation aneurysm locations;



FIG. 5A is a side view of a stent-anchored version of a braid ball implant, FIG. 5B is a side view a stent with a cage for receipt of a braid ball implant;



FIG. 6 is a side view illustrating a folded-section braid ball implant in a PVO application;



FIG. 7 is a side-sectional view of the implant in FIG. 6;



FIGS. 8A and 8B are side-sectional views of an implant shown in stages of manufacture;



FIG. 9 is a side sectional view of an implant in which the folded section is to be utilized at a proximal side of the device;



FIGS. 10A-10E are side views illustrating stages of a folded-section braid ball implant manufacture;



FIGS. 11A and 11B are end views diagrammatically illustrating a technique for presetting the shape of the implant fold;



FIGS. 12A and 12B are side sectional views illustrating folded-section braid ball implants with associated tooling for setting their shape;



FIGS. 13A and 13B are partial side-sectional views illustrating alternate braid/band affixation approaches;



FIG. 14 is a partial side-sectional view illustrating a hub-gluing approach;



FIG. 15 is a partial side view showing a hub-trimming approach;



FIG. 16 is a side-sectional view illustrating another folded-section braid ball implant variation;



FIGS. 17A-17D are side views illustrating stages of the FIG. 16 embodiment manufacture;



FIG. 18 is a side view of a delivery system variation suitable for use in the present invention;



FIG. 19A is a partial side-sectional view of a distal end of another delivery system variation suitable for use in the present invention;



FIG. 19B is an end view from within the implant of the system shown in FIG. 19A;



FIGS. 20A-20F are partial perspective views of implant detachment with a system constructed according to the approach shown in FIGS. 19A and 19B;



FIG. 21 is a perspective view providing an overview of a treatment system according to the present invention;



FIG. 22 is a photograph taken from U.S. Provisional Patent Appl. No. 61/046,670 (incorporated herein by reference) demonstrating actual reduction to practice of a single-layer braid ball device made according to the present invention;



FIGS. 23A and 23B are side-sectional views of the braid ball in isolation and in use, respectively;



FIG. 24 illustrates a suture-melt resistance heater pusher for implant delivery; and



FIGS. 25A-25F illustrate a production path of one implant embodiment encompassed by the current invention.





Variations of the invention from the embodiments pictured are contemplated. Accordingly, depiction of aspects and elements of the invention in the figures is not intended to limit the scope of the invention.


DETAILED DESCRIPTION

Various exemplary embodiments of the invention are described below. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the present invention. Various changes may be made to the invention described and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Turning to FIG. 1A, it shows a first implant 20 according to the present invention. It is formed from tubular braid stock comprising a resilient material such as Nitinol, that defines an open volume (generally round, spherical, ovular, heart-shaped, etc.) in an uncompressed/constrained state.


Implant 20 is set within an aneurysm sac 2 at a vascular bifurcation 4. It is delivered by access through the trunk vessel 6 (e.g., the basilar artery), preferably through a commercially available microcatheter (not shown) with a delivery system as detailed below.


The size of the implant may be selected to fill and extend somewhat out the neck 10 of the aneurysm so the proximal end 22 of the device helps direct blood flow along the surface of the braid from which it is constructed to the branch vessels 8. A distal end of the ball is dome-shaped adjacent a fold 24 in the braid resulting in a two-layer 26, 28 (inner and outer layer, respectively) construction at least where impacted by flow at the neck 10 of the aneurysm. As shown, one or more turns of a coil 30 (e.g., Pt wire) or a band (not shown) may provide a distal radiopaque feature to mark the location of the implant.


The fold 24 in the braid is set at a tighter radius in the implant 40 shown in FIG. 1B. Here, implant 40 is received within a sidewall aneurysm 12 off of a vessel 14. A hub 42 of the implant is facing blood from and directed along the line of vascular access and delivery.


As more easily seen in FIG. 2, implant 40 includes a tie 44 closing an aperture 46 defined by the fold. A radiopaque (e.g., Pt) marker 48 is held by the tie. Such a marker does not interfere with compression of the implant for delivery. Radiographic visibility of the proximal end of the ball may be achieved by virtue of the density of the braid coming together, alone, or a radiopaque (e.g., Pt) band 50 may be added.


Tie 44 may comprise any biocompatible material including Stainless Steel, Titanium, Nitinol (possibly wire that is martensitic at body temperature—commonly referred to as “muscle wire”), suture, etc. An advantage of utilizing wire is that it may simply be twisted to secure its position, along with the marker. In any case, the tie filament should be thin (e.g., about 0.0015 inch diameter or less) if a minimum-radius fold is desired.


Another salient feature of implant 40 concerns the region adjacent hub 42. Specifically, a flared or trumpet-shaped recapture profile 52 is set in the braid to aid in device recapture into the delivery catheter through which the device is advanced. An access port 54 is provided within the hub. This port accepts a delivery system interface. Delivery system construction as well as further optional details of the implant are provided below.


Of course, FIG. 2 shows a ball in an unconstrained condition. When set within an aneurysm, the implant will instead substantially conform to its shape (e.g., as shown in FIG. 1A). Generally, the implant will be oversized somewhat to exert some small load on the aneurysm wall to help maintain a stable position of the ball. However, the ball may be intentionally undersized, especially in a side-wall application (e.g., as shown in FIG. 1B) should it be desired that any hub feature is able to turn with the ball to trail with the blood flow.


Depending on the desired fit, the implant selected by the physician may turn out to be not exactly the right size upon delivery due to variability of aneurysm morphology and/or limitations of medical imaging. It is then that the recapture profile is most useful by facilitating implant retrieval. The first implant can be discarded in favor of a second with a more appropriate size. FIGS. 3A-3C illustrate implants 60, 62 and 64 in a gradation of sizes. Naturally, the sizing interval may be varied. Likewise, the shape may be varied.


In the three examples provided, it is notable that a consistent pore size is maintained toward the center of the ball. Generally it will be desirable to minimize overall pore size. However, the density of the braid that can be achieved in braiding a given tube of braid stock is limited by its diameter and wire size. Accordingly, each of the three balls shown is made of braid incorporating a different number of wires or “ends”. For example, the first implant 60 may be produced from folded-over 72-end material braided over a 6 mm diameter mandrel, the second implant 62 made of folded over 96-end braid from an 8 mm mandrel, and the third implant 64 made of folded-over 144-end braid made on a 10 mm mandrel. Alternately, the larger implants (i.e., those around 10 mm in diameter) may also be made of 96-end braid in order to maintain a lower crossing profile. Specifically, 0.027 inch catheter crossing profile can be achieved when using 96-end braid made of 0.001″ diameter wire. Likewise, at the smaller end of the range (e.g., around 5 mm in diameter) 64-end braid may instead be selected to achieve 0.021 inch crossing profiles.


In any case, braid filaments are shown in pairs within these implants—one from each layer 26, 28. While the organization of the braid is often more random, the double/dual layer construction—on average—results in higher density than might be achieved with a single-layer implant due to limitations on braid density for a given starting diameter of braid.


The implants 70, 72 shown in FIGS. 4A and 4B, respectively, may also be dual layer construction. In which case, they would share their distal configuration with the previous implants 20/40/60. As shown, they are single-layer devices in which the distal end takes the form of an inset hub 74.


Either way, the implants include unique proximal-end configurations. In addition to a ball or bulbous portion 80, each implant includes a flap 76 intended to improve its blood flow disruption potential. Flap 76 included in implant 70 is intended for intra-aneurysmal use. To deliver it as shown, the ball or bulbous portion is first delivered into the aneurysm sac 2. Then, that portion of the device is compressed while still mounted to pusher 100 to deploy the flap section therein. After final positioning is achieved as shown in FIG. 4A, then the pusher locking member(s) received within hub 42 are released. Finally, the pusher is withdrawn into the delivery catheter 110. To assist in the delivery method, one or more additional radiopaque features (such as a band 50 at the proximal end of ball section 80) may be provided so that deployment can be visualized at each stage.


The implant in FIG. 4B requires no such complication in delivery. Because flap 76 is of a size selected only to fill the aneurysm neck, it can be delivered straight-away. Still, intermediate radiopaque features may be desirable to confirm appropriate fit and/or deployment.


As pictured, the ball-and-disk variation of the implant shown in FIG. 4B may only be applicable to smaller-neck aneurysms as compared to the FIG. 4A “acorn” type variation. Generally, the size of the disc will not be significantly larger than the parent/trunk vessel 6 diameter and/or that of the bifurcation region 4. Otherwise, the vasculature will interfere with deployment. As such, the disk may be limited to about 2.5 to about 5 mm in diameter.


While understood better in the context of the implant manufacture steps below, flap 76 may be formed using a simple washer or plate over which the braid is heat set. Otherwise, the forming tool may be curved or dished so that flap 76 better follows the contour of the main implant body.


Flap 76 in the FIG. 4A variation will typically be formed using a concave/convex form in similar fashion. The size of this flap may vary. As shown, its outer extent is roughly the same diameter of the ball portion 80 of the device. It may be smaller and/or cover a lesser extent of the proximal side of implant 70. Generally, flap 76 will cover at least about a third and as much as one-half of body 80. In this way, adequate neck coverage is better insured when employed to treat wide-neck aneurysms.



FIG. 5A is a side view of a stent-anchored version of a braid ball implant. Stent 120 is sized to anchor in the trunk vessel in treating a terminal aneurysm. This way, the ball portion 122 may be sized only to fill the neck of the aneurysm instead of its entire volume. Such an approach may be especially useful for less regularly shaped aneurysms. The device in FIG. 5B is used in a similar fashion, except that a braid-ball implant is introduced and held by a frame or cage 124, after the stent section is set in place.


The frame may comprise a plurality of individual wires 126 secured to a hub 128 of the stent at a proximal end and another hub or platten 130 at the distal end. In another variation, the wires making up the frame are cut from the same tube as the stent cells and any included hub. They may terminate at a distal end within a hub, be swaged within a radiopaque band, welded together, secured by adhesive, or attached by some other means. In any case, they are typically (though not necessarily) attached to form a closed frame. Still, an open frame is contemplated—especially one in which the wires hook backwards (i.e., proximally) to help “catch” the ball when emplaced.


These devices (i.e., those illustrated in FIGS. 5A and 5B) are delivered employing standard techniques, except that “anti-jump”/retrieval features may be incorporated into the stent section. Regardless, at least one row of stent cells 132 is provided in the stent to provide a minimum level of anchoring; however, as many as five or more may be employed—with or without any special delivery anti-jump/control features.


While the stents advantageously include three support extensions 136 for the ball or ball cage, more or fewer may be employed. However, the use of three offers the minimal stable structure available. And where they come together, they operate much like a universal joint to help end-mounted ball/frame successfully interface with the aneurysm to be treated.



FIG. 6 illustrates an altogether different use of the subject implants. Namely, an implant 140 is deployed in a vessel (vs. adjacent a vessel within an aneurysm) to occlude flow. As referenced above, for PVO use the distal end of the ball may include a nub or nipple 142. Indeed, such a feature is advantageous in a construction as illustrated in FIG. 7.


In this side-sectional view, the braid matrix is shown inverted (or everted) at fold 24. A band 144 is set between the inner and outer braid layers. The band closes the end and servers as a marker (especially when it comprises Pt). An adhesive compound 146 (e.g., LOCTITE 3311 or 4014) may be used to fill any residual lumen within the fold aperture. As with the other implants (including those in FIGS. 4A and 4B) the implant may include a recapture profile section 52 at its proximal end, adjacent the hub 42. Likewise, it may include a hub port 54.


Otherwise, both ends of the implant may be closed/plugged with an adhesive or otherwise. Without a delivery system access port, the implant may be delivered using a simple pusher (vs. being fully retrievable and/or repositionable). So-configured, no proximal hub is required either. Indeed, the braid may simply be trimmed and shape set to come together and/or be secured by welding, adhesive or otherwise at the proximal end.


Another optional aspect of the invention is illustrated in FIGS. 8A and 8B. Namely, a folded layer implant 140 is first formed without taking steps to minimize the bend radius at the braid fold 24. While still usable, it may instead be desired to trim off the folded layer to produce a modified implant 140′ as shown in FIG. 8B. Doing so eliminates the bulk, and also changes the implants delivery properties as may be desirable in certain circumstances. The implant becomes more radially compliant and able to fit a wider range of aneurysm sizes because ends 142 of the braid can pass by one another rather than bottoming-out. As such, the same implant 140′ can fill a smaller volume without necessarily extending from the neck of the aneurysm as indicated by dashed in FIG. 8B.


In any case, because of the original construction technique utilizing one tube of braid and folding it over to produce two layers, the (now-separated) layers are well matched to predictably expand and contract. Moreover, once any profile-limiting bends are removed (e.g., by cutting, grinding, etc.) the layers can be reconnected if the adjustability feature described above is not desired. A urethane coating layer 144 or other adhesive (advantageously including radiopaque Barium or Tantalum powder) may be used locally to accomplish such action without a resulting increase in delivery profile.


Still, maintaining the fold in an implant offers numerous advantages in other circumstances—especially when it is formed in such a manner that minimizes wire bend radius/profile. Namely, implants including the fold may offer better size integrity and radial force in circumstances when desired, eliminate any loose fibers at an end of the implant without further processing (such as by polymer application), provide a pocket for a marker and/or tie to suspend a marker, etc.


Moreover, it is to be recognized that the folded end of the implant will not necessarily be set at the distal end of the device. Rather, the folded section 24 may be utilized at a proximal side as shown in FIG. 9. And the aperture 46 formed by the folded section (when held by a ring, band or tie 150) provides a delivery system 110 interface. The opposite end of the implant may have an inset hub (e.g., as illustrated in FIGS. 4A and 4B) or terminate with trimmed ends 142 much like that shown in FIG. 8B (with or without incorporated polymer) or be otherwise configured.


In any case, FIGS. 10A-10D illustrates one approach to constructing a folded-section implant in which the profile of the fold is minimized. As will be appreciated by those with skill in the art, elements of the method may be applied to various of the implant configurations discussed herein.


In these figures, FIG. 10A shows a section of braid 200, tied with suture 202 upon a mandrel 204. The tie is offset from where the braid is cut so that when the braid is inverted as shown in FIG. 10B, the outer layer 28 extends past the inner layer 26. A loose fold 210 is developed and the braid surrounds the implant shaping form 212.


In FIG. 10C, the braid is stretched and secured by wrap 214 (typically Pt or Stainless Steel wire) around the ball form 212. Compression forms 216, 218 are also shown (held by fixturing as indicated by arrows). Fold-side form 216 compresses the fold to a minimum profile during heat setting (e.g., for Nitinol braid at 550° C. for 5 minutes). In this process, the original tie 202 (if made of suture) burns away removing any impediment for achieving a zero or near-zero radius bend at the fold. Opposite form 218 my define a sharp shoulder section (for when that end of the ball is to be trimmed and used as the distal end, in a “floating-layer” ball as described below, etc.) or shape a recapture profile into the braid.


After any such shape-setting, a device perform 220 is ready once the internal form is finally removed as illustrated in FIG. 10D. During this process, the ends of the braid are forced open and typically lose braid integrity/engagement. So that such action does not adversely affect the implant integrity, a “tail” 222 incorporated in the perform 220 should be sufficiently long (i.e., often about 2 cm or more) so as to avoid any damage from unraveled braid ends impacting the intended body 224 of the implant.


If the implant is formed from braid that includes an oxide layer, the perform is next etched, then passivated. However, if pre-etched wire is employed in braiding and any heatsetting performed in a salt pot, vacuum furnace, or using other equipment to minimize oxide formation, the perform may simply be subject to Nitric acid passivation.


Even if additional intermediate process steps are employed, FIG. 10E illustrates a manner in which a band 50 may be added in forming a hub. Specifically, after tying the outer layer 28 with a wrap 226, the band may be threaded over this section. Without the inner layer underneath, the tied section 228 fits within the band 50 such that the band can be sized to tightly fit around both layers of braid (and an optional mandrel 230—the utility of which is discussed below) when advanced to a point adjacent the implant body 224.


An alternative approach to compression-forming the fold during perform shaping to achieve a minimum radius bends in the braid wire is presented in FIGS. 11A and 11B. These figures illustrate a technique for presetting the shape of the implant fold. In FIG. 11A, wedges 240 of a crimper device (e.g., as available through Machine Solutions, Inc. and others) receive braid 200 that is folded over to define a plurality of bends. A mandrel 242 is advantageously set inside the braid. The mandrel limits compression of the braid tube, requiring the bend radius tighten when the aperture 244 formed by the wedges is closed as indicated in FIG. 11B. The shape of the fold is set by heat and/or a combination of strain and heat. The heat may be applied by a torch, within a furnace or, advantageously, by running current though the mandrel. In another approach, a multi-element chuck or collet type device is employed in a similar fashion to the crimper wedges illustrated above.


So-shaped, the overall implant may be formed largely as described in connection with FIGS. 10A-10D without the use of the suture tie or compression form 216. Instead, a permanent fine-wire tie that remains throughout the process may be employed to close the folded end of the ball. This tie can be installed simply by flipping back the folded braid to expose the bends. Alternatively, it can be threaded through and around the bend folds with a needle and tied.


Pre-treating the fold or compression forming it during heatsetting the bulk of the implant is advantageous especially for those cases in which the region adjacent the fold is to be dome shaped. However, when a nubbin is acceptable in the device design given its intended use (e.g., PVO) FIGS. 12A and 12B illustrate another approach. Specifically, a hypotube 250 (or other shaped form including a pocket) is placed over the braid where the braid is trapped between a band 50 and/or the band and mandrel 204 as shown. In addition, as shown in FIG. 12B, a second hypotube 252 (or surface in a form pocket) can abut the distal bend point 254 to further constrain the braid for precision shape setting.


As for setting the remaining shape of the implant or its perform 220, FIG. 12A illustrates the use of a proximal trumpet shaped form 256 to set a smooth recapture profile. In FIG. 12B, the proximal form 258 sets a tight or sharp radius. Such a shape may be desired to achieve higher radial force in the implant due to greater local bending strain.


The implant shown in FIG. 12B seeks to achieve improved anchoring over that in FIG. 12A by virtue of the other noteworthy features illustrated in the drawings. Namely, the cylindrical band 260 shape set in the implant along the otherwise ovular device shape produces edges 262 that interact with vascular tissue with increased local stress to improve anchoring.


Both implants still share a flattened/reduced aspect ratio relative the spherical ball implants previously pictured. Such an aspect ratio allows for greater oversize for anchoring the self-expanding implants in vessel for a resulting length of device. This fact is advantageous given that the focal length of occlusion is often important in treating neurovascular defects in order to inadvertently block adjacent perforator/branch vessels in PVO applications.


Whatever the form of the implant, when a hub is included to secure the braid filaments, certain affixation challenges must be addressed. The hub must be securely fastened to the braid and it may be necessary to minimize the length of the feature. FIGS. 13A and 13B are partial side-sectional views illustrating alternate braid/band affixation approaches. In FIG. 13A, band 50 is set past a trim line for the braid. The small resulting tail 270 provides a surface across which glue 272 can be applied. Once cured (e.g., by UV application) the adhesive is entrained in the braid and forms an edge 274 over which the band cannot pass. If glue is not used, then the braid may be melted with a laser to similarly form an interference feature for the band. Such laser application may weld the braid to an internal band 276 if one is employed. The laser may be applied in a radial direction around the braid, or axially across the trimmed face of the braid.


Especially when utilizing laser energy, an alternative approach as illustrated in FIG. 13B may be employed. Here, by applying laser energy directed axially across the edge of the band(s) and the face of the braid, all of these may be welded together. Even if so-welded, the resulting face may be sealed with polymer adhesive 272.



FIG. 14 illustrates yet another approach to hub fixation. Here, wicking is relied upon for glue/adhesive penetration through the braid under the band to form a bond. A bead 280 of glue is applied to an exposed segment of braid 200 adjacent the band 50. A non-stick (e.g., PTFE coated) mandrel 230 may be situated inside the braid to precisely define a lumen within the glue-impregnated braid. The lumen advantageously operates as a delivery system port. Once the adhesive is cured and the mandrel is removed, a precisely-sized composite wall structure is produced.


The adhesive may be applied evenly around the braid by rotating the assembly as indicated. Other approaches may be utilized as well. In one such approach a plurality of optional access windows 282 may be included in the band to receive and disperse adhesive. Adhesive is also optionally wicked away from the braid 200 by a paper card or absorptive fiber pad 284 (or removed by other means) so that any excess of wicking/flowing adhesive utilized to ensure braid lumen coverage and/or band 50 adhesion does not interfere with the self-expanding action of the implant body 224.


Use of an inner band 276 is also optional. While it occupies space that the braid-and-glue only lumen conserves, including an inner band in the hub assembly 42 may sometimes be desirable for the detachment system interface.


Use of an adjunct hypotube 286 is also optional. This tube, however, offers a useful grip or handle on which to clamp for subsequent trimming. Especially for such use, a thick-walled (e.g., about 0.005″ or greater) tube may be desirable because of additional stability it will yield. As with the band which becomes part of the implant, hypotube 286 may include one or more access windows 282 for adhesive application.


For trimming an implant perform 220 (however it is shaped), FIG. 15 illustrates an approach that coordinates well with the hub affixation approach illustrated in FIG. 14. Specifically adjunct hypotube is captured in a fixture 290 mounted on a slide 292. Lateral adjustment may be provided for in order to align a saw blade 294 (typically a 0.004-0.010 inch diamond-coated wheel) with a gap 296 established between the band and hypotube 286 grip. Once aligned (the cut line may be at the gap, or the band itself may be cut down) the implant is trimmed-off. To aid in handling, the implant may be at least partially constrained in a sheath 298 as shown. A precision cut/trim allows for a band (as trimmed or initially installed) as short as about 0.010 inch in height. A more conservative size (e.g., about 0.020 inch in height) may however be desired to ensure braid capture and detachment system robustness.


After the cut is made, the hub length may be further reduced by grinding its face. After mandrel removal (also cut-off in the trimming procedure) and cleaning in an ultrasonic bath, the hub face may be sealed with adhesive.


Produced using any of the referenced hubbing techniques, another implant variation 300 is illustrated in FIG. 16. Additional steps unique to its manufacture are presented in FIGS. 17A-17D.


The implant differs from those discussed above in that it includes a layer of braid that is not secured at each end of the device. Rather, the inner layer 26 “floats”. Its presence augments implant density, but its fibers adjacent the hub 42 are not forced to bend when the ball is compressed in a sheath for delivery and/or recapture. As such, relatively less force is required for recapture, even when the braid is bent at approximately 90 degrees upon exiting the hub (i.e., without the proximal end of the implant body 224 including a recapture profile in the design).


To produce a ball with the inner braid ends 302 proximate to the hub where the density of the outer braid is highest and best able to prevent individual filaments from the inner layer poking through the braid matrix, an elegant set of manufacturing steps are carried out. Specifically, after starting with an implant perform 220 as shown in FIG. 17A, the outer layer of braid is pulled or pushed off of the intended body 224 of the implant as shown in FIG. 17B. The inner layer of braid is trimmed as shown in FIG. 17C. Wire cutters, scissors or other means may be employed. Finally, the outer layer is returned to its original position as shown in FIG. 17D and the implant perform is further processed.


Such further process may include banding/hubbing, trimming and/or tying the fold aperture closed. However, such tying may advantageously be performed prior to restoring the position of the outer braid while the fold 24 is exposed per FIG. 17B/17C.


Whatever techniques are employed in their construction, the implants are advantageously mounted to a releasable pusher. Delivery system 308 in FIG. 18 is includes a hypotube shaft 312 with cut-out windows 314. The window 314 adjacent the ball hub is critical, the other merely advantageous. A core member 316 (advantageously Nitinol ribbon) exits the proximal window 314 or cutout and re-enters at the second 314. A shoulder/bumper 317 attached to the hypotube abuts a proximal end of the hub 50 to push the implant 40. Alternatively, an external sleeve (not shown) running to the length of the hypotube to a delivery system strain relief 318 and/or hub 320 may be provided. To permit retracting the implant into the delivery catheter (not shown), core member 316 engages the inner surface of the hub lumen (hidden) to retain the implant.


To allow release, the core member is withdrawn into hypotube 310 clearing each of the windows 314 by pulling finger grip 322. At which point, the hypotube may exit the hub port 54 by withdrawing the pusher.


Another detachable delivery system 330 is illustrated in FIGS. 19A and 19B. It is a fully co-axial design in which control wires 332 are pulled to release interference of a head 334 mounted on an anchor wire 336 otherwise unable to pass through a hub port or lumen 54. Because the wires are pulled straight out and only position the anchor wire head to ensure interference (clearly illustrated in FIG. 19B) minimal effort is required. EPTFE coating over at least the control wires is also useful.


The control wires 332 may extend to or past the anchor wire head 334 (the former case illustrated in FIG. 19A). Another option is to limit the control wire length to that of any inner band 276 or overall hub 42 height dimension (as illustrated in FIG. 19B). Note also: FIG. 19A shows a gap between a pusher sleeve 338 and implant hub 50. This representation is for illustration purposes only.


In any case, each of the pusher sleeve lumen 340 and the implant hub lumen/port 54 is preferably sized so that the wires (control wires 332 and anchor wire 336) are received in a close-packed arrangement. In this manner, the implant and pusher sleeve serve as a guide eliminating loading difficulties associated with the wires becoming braided or entwined. Also for loading the system, the anchor wire is typically tensioned to a very slight degree (prior to simple gluing into a handle or using a bias spring incorporated in the handle design) to ensure any gap between the implant and pusher is closed and remains closed in use.



FIGS. 20A-20F illustrate a variation of delivery system 330 is use. The distal end of the detachment system is shown with the hub 42 portion of an implant. FIG. 20A shows the pusher interlock engaged. FIGS. 20B-20D illustrate sequential withdrawal of the control wires 332. Anchor wire 336 may also be individually withdrawn as shown in FIG. 20E. However, it may instead by withdrawn with the detachment system sleeve 338. Indeed, it may be affixed to the sleeve. Still further, it is to be recognized that the control wires need not be pulled one at a time. They can be actuated together. In any case, complete implant separation is illustrated in FIG. 20F.


Finally, FIG. 21 presents an overview of a treatment system 340 including an implant 342 and handle 334. Either one or both of these may be constructed according to the teachings herein. The handle 334 shown includes three knobs. Two knobs 344 are connected to control wires (hidden from view), and the last knob 346 to an anchor wire (hidden from view). A removable locking cap 348 may be included in the handle design as well as a strain relief section 350. The catheter/pusher shaft 338 may comprise a simple extrusion (e.g., PTFE, FEP, PEEK, etc.) or may be constructed using conventional catheter construction techniques and include a liner, braid support and outer jacket (not shown). A loading sheath 352 is typically provided over the pusher shaft. Advantageously, the loading sheath is splittable as is model shown.


After removal from sterile packaging (not shown), the implant is pulled into the loading sheath 352. The loading sheath is received within the hub of the catheter to be used for implant delivery and the implant is advanced into the catheter. Then, the implant may be advanced to and deployed at a treatment site. Or it may be retrieved in exchange for another size implant, else repositioned if desired prior to ultimate detachment like that illustrated in FIGS. 20A-20F.


The subject methods may include each of the physician activities associated with implant positioning and release. As such, methodology implicit to the positioning and deployment of an implant device forms part of the invention. Such methodology may include placing an implant within a brain aneurysm, or at parent vessel targeted for occlusion, or other applications. In some methods, the various acts of implant introduction to an aneurysm or parent vessel are considered.


More particularly, a number of methods according to the present invention involve the manner in which the delivery system operates in reaching a treatment site, for example. Other methods concern the manner in which the system is prepared for delivering an implant, for example attaching the braid ball to the delivery system. Any method herein may be carried out in any order of the recited events which is logically possible, as well as in the recited order of events, or slight modifications of those events or the event order.


Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there is a plurality of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural referents unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth in the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.


The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language. Use of the term “invention” herein is not intended to limit the scope of the claims in any manner. Rather it should be recognized that the “invention” includes the many variations explicitly or implicitly described herein, including those variations that would be obvious to one of ordinary skill in the art upon reading the present specification. Further, it is not intended that any section of this specification (e.g., summary, detailed description, abstract, field of the invention) be accorded special significance in describing the invention relative to another or the claims. All references cited are incorporated by reference in their entirety. Although the foregoing invention has been described in detail for purposes of clarity of understanding, it is contemplated that certain modifications may be practiced within the scope of the appended claims.


Especially for aneurysm treatment, but also for either one of the aforementioned treatments, the form of the ball is very important. In particular, the density of the device is paramount in applications where braid itself is intended to moderate or stop blood flow—allowing thrombosis within a volume formed by the ball.


According to the present invention, braid-ball type implants are provided in braid of sufficient density to moderate blood flow within the volume of the implant. Upon thrombosis, flow thereto is stopped. Alternatively, a blood-barrier covering can be applied to the filamentary structure to immediately stop blood flow into the vascular site, in which the implant volume is set.


In either case, to form thrombosis within the volume of the ball, the filaments of the braid matrix permit filling of the implant with blood when emplaced at a vascular treatment site. This blood then thromboses due to the flow-disruption effect(s).


Unlike Nitinol tube-cut cages that may be suitable for (or assist) in coil retention, the ball devices are adapted to work alone—or in combination with each other to effect a complete treatment. As such, high density braid/mesh is typically required. Namely, braid having at least about 48 ends, typically set at about 90 degrees or greater, in diameters from about 4 to about 8 mm may be employed. At larger diameters (e.g., about 6 to 12 or more), more wire ends (e.g., 64, 72 and upwards) may be employed in forming the balls.


Suitable braid for constructing the balls may be obtained from Secant Medical, Inc. Wire diameters may be in the range of about 0.001 to about 0.003 inches, depending on desired delivery profile (which is typically less than about 0.050 inches). The braid forming the balls may incorporate only one size wire, or may be formed with multiple sizes.


The wire is preferably superelastic NiTi alloy. The metal may be a binary alloy or a ternary alloy to provide additional radiopacity. Alternatively, radiopaque platinum fibers may be included in the braid, or the wire may comprise platinum or gold core Nitinol DFT. Otherwise, wraps or bands (preferably Pt) used to secure the braid wire may serve as the sole radiopaque feature(s).


In any case, the construction approaches described herein enable producing these useful devices. Whether comprising braid alone, or incorporating some further blood-barrier covering (such as a thin urethane film as may be applied by Hantel, Inc. or others), the use of braid presents numerous challenges in managing the termination of multiple wires and in forming the desired structures.


Also included in the invention are detachable implant pushers that utilize a resistance wire heater to thermally sever a suture associated with the implant to effect release. As distinguished from known approaches where an implant is retained by a loop connected back to a delivery system pusher that is withdrawn with the delivery system, the present invention contemplates a leave-behind tether.


Further details, variations, modification and optional features of the invention may be appreciated by review of any of the incorporated patent applications. However, the priority date and subject matter included in the appended claims rely solely on the subject matter filed in U.S. Provisional Patent Application Nos. 61/046,670 and 61/046,594, the earliest patent applications (each filed Apr. 21, 2008) on which U.S. patent application Ser. No. 12/427,620 relies. Selected figures from the '670 and '594 application and all of text from the '594 application—all—incorporated by reference in the parent application hereto is reproduced herein.


Implants


Referring to FIGS. 22-25F, a filamentary implant 402 is formed out of braid to treat vascular sites. Interwoven filaments 404 form a braid matrix 406 that define a self-expandable occlusion device.


As single layer of the braid is provided in which ends of the braid are secured and managed to provide an atraumatic interface. Specifically, ties 410 (as illustrated in FIG. 22) or bands 412 (as illustrated in FIGS. 23A and 23B) secure the ends 414 of the braid from which the implant is constructed.


In the implant variation pictured, the expanded configuration defines an ovoid or roughly spherical shell 418 that is permeable to blood. The braid defining the proximal and distal ends of the implant turns or curves inward to a point where it is secured within the periphery of the shell.


The inversion of the braid provides recessed securement of the braid resulting in atraumatic ends of the implant. The braid filaments optionally extend beyond the securing/securement features in order to define wire filament “tufts” 420 that will further promote thrombosis of blood that enters the ball upon deployment within a patient's vasculature. However configured in regard to braid filament end securement and termination, inset ends of the braid (proximal and distal insets 422/424, respectively) are demonstrated when the implant is in an expanded state to fill an aneurysm 426 off of a vessel 428.


Delivery Systems



FIG. 24 illustrates a detachable catheter/pusher 430, optionally, for use in the present invention. Generally, it includes a resistance wire bridge 432 across insulated conductors 434 (a typical construction). What is unique is that the conductor wires are twinned/twisted along a length of the delivery pusher shaft 438 as shown. This configuration alleviates bending bias/preference. Upon application of voltage, the tip thermally severs the polymer filament (e.g., suture 440) in contact therewith. At least the suture portion is received within the implant 402 (e.g., passing through a braid-securing band 412). The suture is retained in/with the implant upon actuation to release the implant by cutting through the suture with heat. A ball stop 442 that is tied to the suture and retains the filament in/with the implant is also illustrated. Finally, pusher 430 is shown received within a typical microcatheter 444 for vascular access, after passage therethough. Note also, other advantageous delivery system are referenced and described in the incorporated patent application.


Methods of Manufacture


Included in the invention is a method of manufacture including tying-off or otherwise securing a second end of a braid within an interior volume of a ball where other approaches would be impracticable. The technique may be employed in creating the balls (be they spherical or ovaloid in cross-section, etc.) out of one continuous section of braid. In so doing, joints and other delivery profile-increasing features are avoided—as well as potential areas for failure. Accordingly, the subject implants are extremely robust and fully recoverable to their aneurysmal shape as is required when they are delivered through a catheter in low profile. Robust shape recovery is required in treatments targeting distal vasculature, especially the tortuous neurovasculature encountered in human brains.


A detailed example of one process path for implant formation is illustrated in FIGS. 25A-25F. As shown in FIG. 25F a final implant 402 may begin as a section 450 of braided material. The tubular braid stock is secured. As shown, it is tied-off with a wire wrap 410. Such action develops an inset region 424 for the implant body. An opposite end of the braid is then captured in a transfer tube 452. The tube is passed through the volume of the implant and secured with a second tie 410 at the other side.


Additional refinement to the shape over that shown in FIG. 25E may be imparted within a shape-setting form 454. Mandrels 456 including stops 458 received through the securement features may be employed to force apposition of the ball to the shape of the form when pulled apart as indicated by arrows. After shape-setting in the form (as appropriate to the selected material—e.g., as in heat setting superelastic Nitinol) the mandrels are removed and the implant shaping is complete as shown in FIG. 25F. However, these additional forming steps are not necessary given that (in point of fact) the implant in FIG. 22 was produced without employing the same.


Methods of Use


Any one of the subject implants is delivered to a target site employing known percutaneous catheter access techniques. The implant may be secured to a pusher (e.g., pusher 430) used to advance it through the access catheter (e.g., microcatheter 444). Upon emplacement at the treatment site (e.g., cerebral aneurysm 426 as illustrated in FIG. 23A), the implant can be detached. With the exemplary system shown in FIG. 24, the suture 440 passing through the proximal end of the implant 402 is severed by melting it using a resistance heater. This retention/release fiber remains in and with the implant.

Claims
  • 1. A device for implantation within a cerebral aneurysm, the device comprising: a resilient mesh structure comprising a plurality of braided filaments, the mesh structure having a proximal region configured to be positioned within the aneurysm cavity, over a neck of the aneurysm, and a distal region configured to be positioned within the aneurysm cavity, wherein the mesh structure has (a) a compressed state for delivery through an elongated shaft, and (b) an expanded state in which the mesh structure has a width greater than a width of the mesh structure in the compressed state, and wherein the mesh structure comprises an inner layer and an outer layer having respective proximal ends wherein the inner layer transitions to the outer layer at a fold that defines a distal end of the device; anda marker band disposed at the proximal region of the mesh structure, wherein the marker band secures the proximal ends of the inner and outer layers relative to one another.
  • 2. The device of claim 1, wherein, in the expanded state, the mesh structure is configured to self-expand towards a predetermined shape in which a width of the mesh structure decreases proximally towards the marker band.
  • 3. The device of claim 1, wherein the device does not include a marker band at the distal region of the mesh structure.
  • 4. The device of claim 1, wherein the mesh structure is configured to conform to the aneurysm wall in the expanded state.
  • 5. The device of claim 1, wherein at least some of the filaments comprise a shape-memory alloy.
  • 6. The device of claim 1, wherein at least some of the filaments comprise a superelastic material.
  • 7. The device of claim 1, wherein at least some of the filaments are drawn-filled tubes having a platinum core surrounded by an outer layer of Nitinol.
  • 8. The device of claim 1, wherein the proximal region of the mesh structure is rounded.
  • 9. The device of claim 1, wherein, when in the compressed state, the device is configured to be delivered through a microcatheter having an inner diameter of 0.021 inches.
  • 10. The device of claim 1, wherein, when in the compressed state, the device is configured to be delivered through a microcatheter having an inner diameter of 0.027 inches.
  • 11. The device of claim 1, wherein the mesh structure is configured to self-expand when released from a delivery catheter.
  • 12. The device of claim 1, wherein a distance between the inner layer and the outer layer is substantially constant between the distal region and the proximal region of the mesh structure.
  • 13. A device for implantation within a cerebral aneurysm, the device comprising: a resilient mesh structure having a proximal region configured to be positioned within the aneurysm cavity, over a neck of the aneurysm, and a distal region configured to be positioned within the aneurysm cavity, wherein the mesh structure has (a) a compressed state for delivery through an elongated shaft, and (b) an expanded state in which the mesh structure has a width greater than a width of the mesh structure in the compressed state; anda marker band positioned at the proximal region of the mesh structure,wherein the mesh structure comprises a braid that has been folded back on itself to form an inner layer and an outer layer, wherein the inner layer transitions to the outer layer at a fold at a distal end of the mesh structure, and wherein the braid comprises a plurality of braided filaments having first and second ends that are secured to one another at the marker band.
  • 14. The device of claim 13, wherein, in the expanded state, the mesh structure is configured to self-expand towards a predetermined shape in which a width of the mesh structure decreases proximally towards the marker band.
  • 15. The device of claim 13, wherein the device does not include a marker band at the distal region of the mesh structure.
  • 16. The device of claim 13, wherein the mesh structure is configured to conform to the aneurysm wall in the expanded state.
  • 17. The device of claim 13, wherein at least some of the filaments are drawn-filled tubes having a platinum core surrounded by an outer layer of Nitinol.
  • 18. The device of claim 13, wherein, when in the compressed state, the device is configured to be delivered through a microcatheter having an inner diameter of 0.021 inches.
  • 19. The device of claim 13, wherein, when in the compressed state, the device is configured to be delivered through a microcatheter having an inner diameter of 0.027 inches.
  • 20. The device of claim 13, wherein a distance between the inner layer and the outer layer is substantially constant between the distal region and the proximal region of the mesh structure.
CROSS-REFERENCE TO RELATED APPLICATION(S)

The present application is a continuation of U.S. patent application Ser. No. 16/893,431, filed Jun. 4, 2020, which is a continuation of U.S. patent application Ser. No. 15/415,669, filed Jan. 25, 2017, which is a continuation of U.S. patent application Ser. No. 13/470,013, filed May 11, 2012, now U.S. Pat. No. 9,585,669, which is a continuation of U.S. patent application Ser. No. 12/911,034, filed Oct. 25, 2010, now U.S. Pat. No. 9,039,726, which is a continuation of U.S. patent application Ser. No. 12/427,620, filed Apr. 21, 2009, now U.S. Pat. No. 8,142,456, which claims the benefit of each of: U.S. Patent Application Ser. Nos. 61/046,594 and 61/046,670, both filed Apr. 21, 2008; U.S. Patent Application Ser. Nos. 61/083,957 and 61/083,961, both filed Jul. 28, 2008; and U.S. Patent Application Ser. No. 61/145,097, filed Jan. 15, 2009. Each of the foregoing applications is incorporated herein by reference in its entirety.

US Referenced Citations (702)
Number Name Date Kind
3108593 Glassman Oct 1963 A
4425908 Simon Jan 1984 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4655771 Wallsten Apr 1987 A
4768507 Fischell et al. Sep 1988 A
4921484 Hillstead May 1990 A
4998539 Delsanti Mar 1991 A
5026377 Burton et al. Jun 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5104404 Wolff Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5158548 Lau et al. Oct 1992 A
5222971 Willard et al. Jun 1993 A
5250071 Palermo Oct 1993 A
5284488 Sideris Feb 1994 A
5326350 Li Jul 1994 A
5334210 Gianturco Aug 1994 A
5354295 Guglielmi et al. Oct 1994 A
5378239 Termin et al. Jan 1995 A
5405379 Lane Apr 1995 A
5417708 Hall et al. May 1995 A
5425984 Kennedy et al. Jun 1995 A
5499981 Kordis Mar 1996 A
5527338 Purdy Jun 1996 A
5545208 Wolff et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5549635 Solar Aug 1996 A
5624461 Mariant Apr 1997 A
5634942 Chevillon et al. Jun 1997 A
5645558 Horton Jul 1997 A
5662703 Yurek et al. Sep 1997 A
5669931 Kupiecki et al. Sep 1997 A
5690671 Mcgurk et al. Nov 1997 A
5702419 Berry et al. Dec 1997 A
5713907 Wholey et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5728906 Eguchi et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5741333 Frid Apr 1998 A
5749891 Ken et al. May 1998 A
5749895 Sawyer et al. May 1998 A
5749919 Blanc May 1998 A
5749920 Quiachon et al. May 1998 A
5766151 Valley et al. Jun 1998 A
5814062 Sepetka et al. Sep 1998 A
5823198 Jones et al. Oct 1998 A
5830230 Berryman et al. Nov 1998 A
5846261 Kotula et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5879366 Shaw et al. Mar 1999 A
5908435 Samuels Jun 1999 A
5911731 Pham et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5925060 Forber Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar et al. Aug 1999 A
5935362 Petrick Aug 1999 A
5941249 Maynard Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5951599 Mccrory Sep 1999 A
5957948 Mariant Sep 1999 A
5964797 Ho Oct 1999 A
5976162 Doan et al. Nov 1999 A
5976169 Imran Nov 1999 A
5980554 Lenker et al. Nov 1999 A
6001092 Mirigian et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6022374 Imran Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6033423 Ken et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6059813 Vrba et al. May 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6086577 Ken et al. Jul 2000 A
6090125 Horton Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099526 Whayne et al. Aug 2000 A
6106530 Harada Aug 2000 A
6110191 Dehdashtian et al. Aug 2000 A
6123715 Amplatz Sep 2000 A
6139564 Teoh Oct 2000 A
6152144 Lesh et al. Nov 2000 A
6159531 Dang et al. Dec 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6183495 Lenker et al. Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6221086 Forber Apr 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6261305 Marotta et al. Jul 2001 B1
6280412 Pederson, Jr. et al. Aug 2001 B1
6299619 Greene, Jr. et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6309367 Boock Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6325820 Khosravi et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6332576 Colley et al. Dec 2001 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6371980 Rudakov et al. Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6383174 Eder May 2002 B1
6391037 Greenhalgh May 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6428558 Jones et al. Aug 2002 B1
6443972 Bosma et al. Sep 2002 B1
6447531 Amplatz Sep 2002 B1
6451050 Rudakov et al. Sep 2002 B1
6454780 Wallace Sep 2002 B1
6494884 Gifford, Iii et al. Dec 2002 B2
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6530934 Jacobsen et al. Mar 2003 B1
6544278 Vrba et al. Apr 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6569179 Teoh et al. May 2003 B2
6579302 Duerig et al. Jun 2003 B2
6579303 Amplatz Jun 2003 B2
6585748 Jeffree Jul 2003 B1
6585756 Strecker Jul 2003 B1
6589256 Forber Jul 2003 B2
6589265 Palmer et al. Jul 2003 B1
6591472 Noone et al. Jul 2003 B1
6592605 Lenker et al. Jul 2003 B2
6599308 Amplatz Jul 2003 B2
6602261 Greene, Jr. et al. Aug 2003 B2
6605101 Schaefer et al. Aug 2003 B1
6605102 Mazzocchi et al. Aug 2003 B1
6605111 Bose et al. Aug 2003 B2
6607551 Sullivan et al. Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635069 Teoh et al. Oct 2003 B1
6652555 Vantassel et al. Nov 2003 B1
6652556 Vantassel et al. Nov 2003 B1
6666882 Bose et al. Dec 2003 B1
6666883 Seguin et al. Dec 2003 B1
6669717 Marotta et al. Dec 2003 B2
6669721 Bose et al. Dec 2003 B1
6676696 Marotta et al. Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6682546 Amplatz Jan 2004 B2
6689150 Vantassel et al. Feb 2004 B1
6689486 Ho et al. Feb 2004 B2
6695876 Marotta et al. Feb 2004 B1
6698877 Urlaub et al. Mar 2004 B2
6699274 Stinson Mar 2004 B2
6709465 Mitchell et al. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6723112 Ho et al. Apr 2004 B2
6723116 Taheri Apr 2004 B2
6730108 Van Tassel et al. May 2004 B2
6746468 Sepetka et al. Jun 2004 B1
6746890 Gupta et al. Jun 2004 B2
6780196 Chin et al. Aug 2004 B2
6792979 Konya et al. Sep 2004 B2
6797083 Peterson Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
RE38653 Igaki et al. Nov 2004 E
6811560 Jones et al. Nov 2004 B2
6855153 Saadat Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
RE38711 Igaki et al. Mar 2005 E
6860893 Wallace et al. Mar 2005 B2
6878384 Cruise et al. Apr 2005 B2
6905503 Gifford, Iii et al. Jun 2005 B2
6936055 Ken et al. Aug 2005 B1
6949103 Mazzocchi et al. Sep 2005 B2
6949113 Van Tassel et al. Sep 2005 B2
6953472 Palmer et al. Oct 2005 B2
6979341 Scribner et al. Dec 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6991617 Hektner et al. Jan 2006 B2
6994092 Van Der Burg et al. Feb 2006 B2
6994717 Konya et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7014645 Greene, Jr. et al. Mar 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7029487 Greene, Jr. et al. Apr 2006 B2
7029949 Farnworth et al. Apr 2006 B2
7033375 Mazzocchi et al. Apr 2006 B2
7048752 Mazzocchi et al. May 2006 B2
7063679 Maguire et al. Jun 2006 B2
7070607 Murayama et al. Jul 2006 B2
7070609 West Jul 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7128073 Van Der Burg et al. Oct 2006 B1
7128736 Abrams et al. Oct 2006 B1
7153323 Teoh et al. Dec 2006 B1
7169177 Obara Jan 2007 B2
7195636 Avellanet et al. Mar 2007 B2
7211109 Thompson May 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7244267 Huter et al. Jul 2007 B2
7261720 Stevens et al. Aug 2007 B2
7303571 Makower et al. Dec 2007 B2
7306622 Jones et al. Dec 2007 B2
7326225 Ferrera et al. Feb 2008 B2
7331980 Dubrul et al. Feb 2008 B2
7367985 Mazzocchi et al. May 2008 B2
7367986 Mazzocchi et al. May 2008 B2
7371250 Mazzocchi et al. May 2008 B2
7393358 Malewicz Jul 2008 B2
7404820 Mazzocchi et al. Jul 2008 B2
7410482 Murphy et al. Aug 2008 B2
7410492 Mazzocchi et al. Aug 2008 B2
7413622 Peterson Aug 2008 B2
7419503 Pulnev et al. Sep 2008 B2
7442200 Mazzocchi et al. Oct 2008 B2
7481821 Fogarty et al. Jan 2009 B2
7485088 Murphy et al. Feb 2009 B2
7491214 Greene, Jr. et al. Feb 2009 B2
7556635 Mazzocchi et al. Jul 2009 B2
7566338 Mazzocchi et al. Jul 2009 B2
7569066 Gerberding et al. Aug 2009 B2
7572273 Mazzocchi et al. Aug 2009 B2
7572288 Cox Aug 2009 B2
7575590 Watson Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7601160 Richter Oct 2009 B2
7608088 Jones et al. Oct 2009 B2
7621928 Thramann et al. Nov 2009 B2
7632296 Malewicz Dec 2009 B2
7670355 Mazzocchi et al. Mar 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678130 Mazzocchi et al. Mar 2010 B2
7682390 Seguin Mar 2010 B2
7691124 Balgobin Apr 2010 B2
7695488 Berenstein et al. Apr 2010 B2
7699056 Tran et al. Apr 2010 B2
7708754 Balgobin et al. May 2010 B2
7727189 Vantassel et al. Jun 2010 B2
7744583 Seifert et al. Jun 2010 B2
7744652 Morsi Jun 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7922732 Mazzocchi et al. Apr 2011 B2
7955343 Makower et al. Jun 2011 B2
7972359 Kreidler Jul 2011 B2
7976527 Cragg et al. Jul 2011 B2
RE42625 Guglielmi Aug 2011 E
7993364 Morsi Aug 2011 B2
RE42758 Ken et al. Sep 2011 E
8012210 Lin et al. Sep 2011 B2
8016869 Nikolchev Sep 2011 B2
8016872 Parker Sep 2011 B2
8043326 Hancock et al. Oct 2011 B2
8062379 Morsi Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8137293 Zhou et al. Mar 2012 B2
8142454 Rosqueta et al. Mar 2012 B2
8202280 Richter Jun 2012 B2
8211160 Garrison et al. Jul 2012 B2
8221445 Van Tassel et al. Jul 2012 B2
8261648 Marchand et al. Sep 2012 B1
8298257 Sepetka et al. Oct 2012 B2
8333783 Braun et al. Dec 2012 B2
8343167 Henson Jan 2013 B2
8361104 Jones et al. Jan 2013 B2
8361138 Adams Jan 2013 B2
8398670 Amplatz et al. Mar 2013 B2
8425541 Masters et al. Apr 2013 B2
8430012 Marchand et al. Apr 2013 B1
8454681 Holman et al. Jun 2013 B2
8470013 Duggal et al. Jun 2013 B2
8597320 Sepetka et al. Dec 2013 B2
8603128 Greene, Jr. et al. Dec 2013 B2
8715317 Janardhan et al. May 2014 B1
8834515 Win et al. Sep 2014 B2
8906057 Connor et al. Dec 2014 B2
8974512 Aboytes et al. Mar 2015 B2
8998947 Aboytes et al. Apr 2015 B2
9211202 Strother et al. Dec 2015 B2
9301769 Brady et al. Apr 2016 B2
9314248 Molaei Apr 2016 B2
9486224 Riina et al. Nov 2016 B2
9629636 Fogarty et al. Apr 2017 B2
9833309 Levi et al. Dec 2017 B2
9844380 Furey Dec 2017 B2
9907684 Connor et al. Mar 2018 B2
9962146 Hebert et al. May 2018 B2
10028745 Morsi Jul 2018 B2
20010000797 Mazzocchi May 2001 A1
20010001835 Greene et al. May 2001 A1
20010007082 Dusbabek et al. Jul 2001 A1
20010012949 Forber Aug 2001 A1
20010051822 Stack et al. Dec 2001 A1
20020013599 Limon et al. Jan 2002 A1
20020013618 Marotta et al. Jan 2002 A1
20020026210 Abdel-gawwad Feb 2002 A1
20020042628 Chin et al. Apr 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020062145 Rudakov et al. May 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020119177 Bowman et al. Aug 2002 A1
20020147462 Mair et al. Oct 2002 A1
20020165572 Saadat Nov 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020193812 Patel et al. Dec 2002 A1
20020193813 Helkowski et al. Dec 2002 A1
20030004533 Dieck et al. Jan 2003 A1
20030004538 Secrest et al. Jan 2003 A1
20030004568 Ken et al. Jan 2003 A1
20030018294 Cox Jan 2003 A1
20030028209 Teoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030055440 Jones et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030093111 Ken et al. May 2003 A1
20030113478 Dang et al. Jun 2003 A1
20030114918 Garrison et al. Jun 2003 A1
20030149490 Ashman Aug 2003 A1
20030171739 Murphy et al. Sep 2003 A1
20030171770 Kusleika et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187473 Berenstein et al. Oct 2003 A1
20030195553 Wallace Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199919 Palmer et al. Oct 2003 A1
20030212419 West Nov 2003 A1
20040015224 Armstrong et al. Jan 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040044391 Porter Mar 2004 A1
20040064093 Hektner et al. Apr 2004 A1
20040098027 Teoh et al. May 2004 A1
20040098030 Makower et al. May 2004 A1
20040106945 Thramann et al. Jun 2004 A1
20040106977 Sullivan et al. Jun 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040115164 Pierce et al. Jun 2004 A1
20040122467 Vantassel et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040138758 Kronengold et al. Jul 2004 A1
20040143239 Zhou et al. Jul 2004 A1
20040143286 Johnson et al. Jul 2004 A1
20040153119 Kusleika et al. Aug 2004 A1
20040161451 Pierce et al. Aug 2004 A1
20040162606 Thompson Aug 2004 A1
20040172056 Guterman Sep 2004 A1
20040172121 Eidenschink et al. Sep 2004 A1
20040181253 Sepetka et al. Sep 2004 A1
20040186562 Cox Sep 2004 A1
20040193206 Gerberding et al. Sep 2004 A1
20040215229 Coyle Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040267346 Shelso Dec 2004 A1
20050010281 Yodfat et al. Jan 2005 A1
20050021077 Chin et al. Jan 2005 A1
20050033408 Jones et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050049625 Shaya et al. Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050096728 Ramer May 2005 A1
20050096732 Marotta et al. May 2005 A1
20050107823 Leone et al. May 2005 A1
20050131443 Abdel-Gawwad Jun 2005 A1
20050222580 Gifford et al. Oct 2005 A1
20050222605 Greenhalgh et al. Oct 2005 A1
20050228434 Amplatz Oct 2005 A1
20050267510 Razack Dec 2005 A1
20050267511 Marks et al. Dec 2005 A1
20050267527 Sandoval et al. Dec 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050277978 Greenhalgh Dec 2005 A1
20050278023 Zwirkoski Dec 2005 A1
20050288763 Andreas et al. Dec 2005 A1
20060034883 Dang et al. Feb 2006 A1
20060052816 Bates et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060074475 Gumm Apr 2006 A1
20060106421 Teoh May 2006 A1
20060116709 Sepetka et al. Jun 2006 A1
20060116712 Sepetka et al. Jun 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116714 Sepetka et al. Jun 2006 A1
20060122548 Abrams Jun 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060190076 Taheri Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060200234 Hines Sep 2006 A1
20060206140 Shaolian et al. Sep 2006 A1
20060206198 Churchwell et al. Sep 2006 A1
20060206199 Churchwell et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060217799 Mailänder et al. Sep 2006 A1
20060224183 Freudenthal Oct 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060235464 Avellanet et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241686 Ferrera et al. Oct 2006 A1
20060241690 Amplatz et al. Oct 2006 A1
20060247680 Amplatz Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060264907 Eskridge et al. Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060271162 Vito et al. Nov 2006 A1
20060282152 Beyerlein et al. Dec 2006 A1
20060292206 Kim et al. Dec 2006 A1
20060293744 Peckham et al. Dec 2006 A1
20070003594 Brady et al. Jan 2007 A1
20070005125 Berenstein et al. Jan 2007 A1
20070010850 Balgobin et al. Jan 2007 A1
20070014831 Sung et al. Jan 2007 A1
20070016243 Ramaiah et al. Jan 2007 A1
20070021816 Rudin Jan 2007 A1
20070050017 Sims et al. Mar 2007 A1
20070083226 Buiser et al. Apr 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070093889 Wu et al. Apr 2007 A1
20070100415 Licata et al. May 2007 A1
20070100426 Rudakov et al. May 2007 A1
20070106311 Wallace et al. May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070135907 Wilson et al. Jun 2007 A1
20070150045 Ferrera Jun 2007 A1
20070162104 Frid Jul 2007 A1
20070167876 Euteneuer et al. Jul 2007 A1
20070167877 Euteneuer et al. Jul 2007 A1
20070167972 Euteneuer et al. Jul 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070175536 Monetti et al. Aug 2007 A1
20070179520 West Aug 2007 A1
20070185442 Euteneuer et al. Aug 2007 A1
20070185443 Euteneuer et al. Aug 2007 A1
20070185444 Euteneuer et al. Aug 2007 A1
20070185457 Euteneuer et al. Aug 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070191924 Rudakov Aug 2007 A1
20070198059 Patel et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070221230 Thompson et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070233224 Leynov et al. Oct 2007 A1
20070233244 Lopez et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070276426 Euteneuer Nov 2007 A1
20070276427 Euteneuer Nov 2007 A1
20070282373 Ashby et al. Dec 2007 A1
20070288083 Hines Dec 2007 A1
20070293935 Olsen et al. Dec 2007 A1
20080009934 Schneider et al. Jan 2008 A1
20080021535 Leopold et al. Jan 2008 A1
20080033366 Matson et al. Feb 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080045996 Makower et al. Feb 2008 A1
20080045997 Balgobin et al. Feb 2008 A1
20080051705 Von Oepen et al. Feb 2008 A1
20080058856 Ramaiah et al. Mar 2008 A1
20080065141 Holman et al. Mar 2008 A1
20080065145 Carpenter Mar 2008 A1
20080081763 Swetlin et al. Apr 2008 A1
20080082176 Slazas Apr 2008 A1
20080086196 Truckai et al. Apr 2008 A1
20080097495 Feller et al. Apr 2008 A1
20080109057 Calabria et al. May 2008 A1
20080109063 Hancock et al. May 2008 A1
20080114391 Dieck et al. May 2008 A1
20080114436 Dieck et al. May 2008 A1
20080114439 Ramaiah et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080125806 Mazzocchi et al. May 2008 A1
20080125848 Kusleika et al. May 2008 A1
20080125852 Garrison et al. May 2008 A1
20080132820 Buckman et al. Jun 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080140177 Hines Jun 2008 A1
20080154286 Abbott et al. Jun 2008 A1
20080195139 Donald et al. Aug 2008 A1
20080200945 Amplatz et al. Aug 2008 A1
20080200979 Dieck et al. Aug 2008 A1
20080219533 Grigorescu Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080243226 Fernandez et al. Oct 2008 A1
20080249562 Cahill Oct 2008 A1
20080255603 Naor et al. Oct 2008 A1
20080262598 Elmaleh Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080319533 Lehe Dec 2008 A1
20090018637 Paul, Jr. et al. Jan 2009 A1
20090024224 Chen et al. Jan 2009 A1
20090025820 Adams Jan 2009 A1
20090043375 Rudakov et al. Feb 2009 A1
20090056722 Swann Mar 2009 A1
20090062899 Dang et al. Mar 2009 A1
20090069806 De La Mora et al. Mar 2009 A1
20090076540 Marks et al. Mar 2009 A1
20090082803 Adams Mar 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090112249 Miles et al. Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090118811 Moloney May 2009 A1
20090125094 Rust May 2009 A1
20090125119 Obermiller et al. May 2009 A1
20090143849 Ozawa et al. Jun 2009 A1
20090143851 Paul, Jr. Jun 2009 A1
20090148492 Dave et al. Jun 2009 A1
20090155367 Neuwirth et al. Jun 2009 A1
20090187214 Amplatz et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090204145 Matthews Aug 2009 A1
20090210047 Amplatz et al. Aug 2009 A1
20090216307 Kaufmann et al. Aug 2009 A1
20090228029 Lee Sep 2009 A1
20090228093 Taylor et al. Sep 2009 A1
20090259202 Leeflang et al. Oct 2009 A1
20090264914 Riina et al. Oct 2009 A1
20090264978 Dieck et al. Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287292 Becking et al. Nov 2009 A1
20090287294 Rosqueta et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090297582 Meyer et al. Dec 2009 A1
20090306702 Miloslavski et al. Dec 2009 A1
20090318892 Aboytes et al. Dec 2009 A1
20090318941 Sepetka et al. Dec 2009 A1
20090318948 Davis et al. Dec 2009 A1
20090319023 Hildebrand et al. Dec 2009 A1
20100004726 Hancock et al. Jan 2010 A1
20100004761 Flanders et al. Jan 2010 A1
20100023048 Mach Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100030200 Strauss et al. Feb 2010 A1
20100030220 Truckai et al. Feb 2010 A1
20100036390 Gumm Feb 2010 A1
20100036410 Krolik et al. Feb 2010 A1
20100042133 Ramzipoor et al. Feb 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100087908 Hilaire et al. Apr 2010 A1
20100094335 Gerberding et al. Apr 2010 A1
20100106178 Obermiller et al. Apr 2010 A1
20100131002 Connor et al. May 2010 A1
20100139465 Christian et al. Jun 2010 A1
20100144895 Porter Jun 2010 A1
20100152767 Greenhalgh et al. Jun 2010 A1
20100174269 Tompkins et al. Jul 2010 A1
20100185271 Zhang Jul 2010 A1
20100222802 Gillespie, Jr. et al. Sep 2010 A1
20100228184 Mavani et al. Sep 2010 A1
20100249830 Nelson Sep 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100256527 Lippert et al. Oct 2010 A1
20100256528 Lippert et al. Oct 2010 A1
20100256601 Lippert et al. Oct 2010 A1
20100256602 Lippert et al. Oct 2010 A1
20100256603 Lippert et al. Oct 2010 A1
20100256604 Lippert et al. Oct 2010 A1
20100256605 Lippert et al. Oct 2010 A1
20100256606 Lippert et al. Oct 2010 A1
20100262014 Huang Oct 2010 A1
20100268201 Tieu et al. Oct 2010 A1
20100268260 Riina et al. Oct 2010 A1
20100274276 Chow et al. Oct 2010 A1
20100298791 Jones et al. Nov 2010 A1
20100312061 Hess et al. Dec 2010 A1
20100312270 Mcguckin, Jr. et al. Dec 2010 A1
20100331948 Turovskiy et al. Dec 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110046658 Connor et al. Feb 2011 A1
20110054519 Neuss Mar 2011 A1
20110077620 Debeer Mar 2011 A1
20110082493 Samson et al. Apr 2011 A1
20110106234 Grandt May 2011 A1
20110125110 Cotton May 2011 A1
20110137332 Sepetka et al. Jun 2011 A1
20110137405 Wilson et al. Jun 2011 A1
20110144669 Becking et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110166588 Connor et al. Jul 2011 A1
20110184452 Huynh et al. Jul 2011 A1
20110184453 Levy et al. Jul 2011 A1
20110196415 Ujiie et al. Aug 2011 A1
20110202085 Loganathan et al. Aug 2011 A1
20110208227 Becking Aug 2011 A1
20110224776 Sepetka et al. Sep 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110251699 Ladet Oct 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110276120 Gilson et al. Nov 2011 A1
20110313447 Strauss et al. Dec 2011 A1
20110319926 Becking et al. Dec 2011 A1
20120010644 Sideris et al. Jan 2012 A1
20120022572 Braun et al. Jan 2012 A1
20120041470 Shrivastava et al. Feb 2012 A1
20120041472 Tan et al. Feb 2012 A1
20120065720 Strauss et al. Mar 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120101561 Porter Apr 2012 A1
20120116350 Strauss et al. May 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120143243 Hill et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120165803 Bencini et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120226343 Vo et al. Sep 2012 A1
20120239074 Aboytes et al. Sep 2012 A1
20120245674 Molaei et al. Sep 2012 A1
20120245675 Molaei et al. Sep 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120283769 Cruise et al. Nov 2012 A1
20120310269 Fearnot et al. Dec 2012 A1
20120316598 Becking et al. Dec 2012 A1
20120316632 Gao Dec 2012 A1
20120323271 Obermiller et al. Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330347 Becking et al. Dec 2012 A1
20120330348 Strauss et al. Dec 2012 A1
20130018451 Grabowski et al. Jan 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130066360 Becking et al. Mar 2013 A1
20130085522 Becking et al. Apr 2013 A1
20130092013 Thompson et al. Apr 2013 A1
20130116722 Aboytes et al. May 2013 A1
20130123830 Becking et al. May 2013 A1
20130211495 Halden et al. Aug 2013 A1
20130233160 Marchand et al. Sep 2013 A1
20130239790 Thompson et al. Sep 2013 A1
20130245667 Marchand et al. Sep 2013 A1
20130245670 Fan Sep 2013 A1
20130268053 Molaei et al. Oct 2013 A1
20130274862 Cox et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
20130304179 Bialas et al. Nov 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005713 Bowman Jan 2014 A1
20140012307 Franano et al. Jan 2014 A1
20140058420 Hannes et al. Feb 2014 A1
20140135810 Divino et al. May 2014 A1
20140135811 Divino et al. May 2014 A1
20140135812 Divino et al. May 2014 A1
20140316012 Freyman et al. Oct 2014 A1
20140371734 Truckai Dec 2014 A1
20150216684 Enzmann et al. Aug 2015 A1
20150250628 Monstadt et al. Sep 2015 A1
20150272590 Aboytes et al. Oct 2015 A1
20150313737 Tippett et al. Nov 2015 A1
20150327843 Garrison Nov 2015 A1
20150342613 Aboytes et al. Dec 2015 A1
20160022445 Ruvalcaba et al. Jan 2016 A1
20160030050 Franano et al. Feb 2016 A1
20160066921 Seifert et al. Mar 2016 A1
20160135984 Rudakov et al. May 2016 A1
20160206320 Connor Jul 2016 A1
20160206321 Connor Jul 2016 A1
20170150971 Hines Jun 2017 A1
20170156903 Shobayashi Jun 2017 A1
20170189035 Porter Jul 2017 A1
20170266023 Thomas Sep 2017 A1
20170340333 Badruddin et al. Nov 2017 A1
20170367708 Mayer et al. Dec 2017 A1
20180049859 Stoppenhagen et al. Feb 2018 A1
20180125686 Lu May 2018 A1
20180140305 Connor May 2018 A1
20180161185 Kresslein et al. Jun 2018 A1
20180193025 Walzman Jul 2018 A1
20180193026 Yang et al. Jul 2018 A1
20180206852 Moeller Jul 2018 A1
20190053811 Garza et al. Feb 2019 A1
20190282242 Divino et al. Sep 2019 A1
20190343532 Divino et al. Nov 2019 A1
20200061099 Li et al. Feb 2020 A1
20200367904 Becking et al. Nov 2020 A1
Foreign Referenced Citations (96)
Number Date Country
2607529 Apr 2008 CA
101472537 Jul 2009 CN
102083493 Jun 2011 CN
1283434 Nov 1968 DE
102008028308 Apr 2009 DE
102010050569 May 2012 DE
102011011510 Aug 2012 DE
102011102933 Dec 2012 DE
0717969 Jun 1996 EP
0743047 Nov 1996 EP
0855170 Jul 1998 EP
0775470 Mar 1999 EP
1188414 Mar 2002 EP
1621148 Feb 2006 EP
1637176 Mar 2006 EP
1752112 Feb 2007 EP
1813213 Aug 2007 EP
1923019 May 2008 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2208483 Jul 2010 EP
2279023 Feb 2011 EP
2363075 Sep 2011 EP
2496299 Sep 2012 EP
2675402 Dec 2013 EP
2556210 Apr 1988 FR
2890306 Mar 2007 FR
11506686 Jun 1999 JP
2003520103 Jul 2003 JP
2003524434 Aug 2003 JP
2004049585 Feb 2004 JP
2005522266 Jul 2005 JP
2005261951 Sep 2005 JP
2006506201 Feb 2006 JP
2008521492 Jun 2008 JP
2008541832 Nov 2008 JP
4673987 Jan 2011 JP
WO 8800813 Feb 1988 WO
WO 9406502 Mar 1994 WO
WO 9601591 Jan 1996 WO
WO 9726939 Jul 1997 WO
WO 9903404 Jan 1999 WO
WO 9905977 Feb 1999 WO
WO 9908607 Feb 1999 WO
WO 9908743 Feb 1999 WO
WO 9940873 Aug 1999 WO
WO 9962432 Dec 1999 WO
WO 0057815 Oct 2000 WO
WO 0193782 Dec 2001 WO
WO 0200139 Jan 2002 WO
WO 02071977 Sep 2002 WO
WO 03011151 Feb 2003 WO
WO 03037191 May 2003 WO
WO 2005117718 Dec 2005 WO
WO 2006026744 Mar 2006 WO
WO 2006034149 Mar 2006 WO
WO 2006034166 Mar 2006 WO
WO 2006052322 May 2006 WO
WO 2006091891 Aug 2006 WO
WO 2006119422 Nov 2006 WO
WO 2007006139 Jan 2007 WO
WO 2007047851 Apr 2007 WO
WO 2007076480 Jul 2007 WO
WO 2007095031 Aug 2007 WO
WO 2007121405 Oct 2007 WO
WO 2008022327 Feb 2008 WO
WO 2008074027 Jun 2008 WO
WO 2008109228 Sep 2008 WO
WO 2008151204 Dec 2008 WO
WO 2008157507 Dec 2008 WO
WO 2009014528 Jan 2009 WO
WO 2009076515 Jun 2009 WO
WO 2009132045 Oct 2009 WO
WO 2009134337 Nov 2009 WO
WO 2009135166 Nov 2009 WO
WO 2010009019 Jan 2010 WO
WO 2010027363 Mar 2010 WO
WO 2010028300 Mar 2010 WO
WO 2010030991 Mar 2010 WO
WO 2010077599 Jul 2010 WO
WO 2010147808 Dec 2010 WO
WO 2011057002 May 2011 WO
WO 2011057277 May 2011 WO
WO 2011066962 Jun 2011 WO
WO 2011095966 Aug 2011 WO
WO 2011130081 Oct 2011 WO
WO 2011153304 Dec 2011 WO
WO 2012034135 Mar 2012 WO
WO 2012068175 May 2012 WO
WO 2012112749 Aug 2012 WO
WO 2012166804 Dec 2012 WO
WO 2013112944 Aug 2013 WO
WO 2013138615 Sep 2013 WO
WO 2013138615 Sep 2014 WO
WO 2017074411 May 2017 WO
WO 2018051187 Mar 2018 WO
Non-Patent Literature Citations (3)
Entry
Hill, et al., “Initial Results of the AMO LA TZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004.
Ronnen, “Amplatzer Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007.
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040.
Related Publications (1)
Number Date Country
20220022886 A1 Jan 2022 US
Provisional Applications (5)
Number Date Country
61145097 Jan 2009 US
61083961 Jul 2008 US
61083957 Jul 2008 US
61046670 Apr 2008 US
61046594 Apr 2008 US
Continuations (5)
Number Date Country
Parent 16893431 Jun 2020 US
Child 17408329 US
Parent 15415669 Jan 2017 US
Child 16893431 US
Parent 13470013 May 2012 US
Child 15415669 US
Parent 12911034 Oct 2010 US
Child 13470013 US
Parent 12427620 Apr 2009 US
Child 12911034 US